











Progressive Control Pathway for Foot-and-Mouth Disease (PCP-FMD)

Dr Bouda Vosough Ahmadi

Livetsock Health Economist EuFMD

CAREC Policy Dialogue Meeting Astana, 23-25th April 2019













Outline of the presentation

- 1. Global FMD control strategy
- 2. An overview of PCP-FMD
- 3. Objectives and principles
- 4. PCP-FMD and national strategic plans
- 5. Regional initiatives
- 6. Costs and benefits
- 7. Public-Private Partnerships
- 8. Summary














Global FMD Control Strategy















What is a Progressive Control Pathway (PCP)?

- Step-wise approaches are increasingly used for the reduction, elimination and eradication of a range of major livestock and zoonotic diseases including: FMD, PPR, Rabies, AAT
- PCPs provide systemic frameworks for planning and evaluating field interventions and enable realistic disease control objectives to be defined and achieved
- PCPs have been used since 2008 by FAO and become adopted as joint tools with the OIE (FMD, PPR), or developed/owned by global alliances (rabies, AAT)













PCP-FMD

- Developed by FAO and EuFMD, firstly launched in Shiraz, Iran back in 2008
- The PCP-FMD consists of Stages that progressively increase the level of FMD control
- Consist of set of activities focused on identifying and addressing the risk for FMD introduction and spread
- Intended to assist FMD-endemic countries to progressively reduce the impact and burden of FMD














PCP-FMD stages and domains















Minimum requirements & progress indicators

	Minimum stage compliance requirements	Outcome indicator to be achieved
Stage 1	Measures to understand the risk of FMD	Risk assessment plan
Stage 2	Risk-based measures are implemented and monitored	Risk-based strategic plan
Stage 3	Early detection and quick response to all outbreaks of foot and mouth disease	Official control programme
Stage 4	The approved National Official Control Program is implemented and monitored	OIE Approval of the Official Control Programme
Status	OiC	OIE free status with vaccination
Status		OIE free status without vaccination













Principles of PCP-FMD

- Applied in achievable steps
- Non prescriptive; focused on results
- Prioritizes risk "hotspots" using risk analysis
- Economic efficiency in using limited resources
- Evidence based by monitoring and evaluation
- Not for free countries want to regain FMD freedom













West Eurasia Regional Roadmap

Early stage 2008-14

Regional cooperation among Eurasian countries for the progressive control of FMD through *public and private partnerships* leading towards freedom of clinical disease by 2020 for regional economic development, food security, and poverty alleviation.



Later on 2015

Regional cooperation among Eurasian countries for the progressive control of FMD leading towards freedom of clinical disease by 2025 for regional economic development, food security, and poverty alleviation















Evaluation of PCP progress: national vs regional

Annual roadmap meetings

Multi-disease approach
Other stepwise approaches
developed (e.g. PPR,
brucellosis, rabies)

Epi and Lab Networks



Remaining in early stages

Analyse reasons of lack of progress

Guidance/mentoring between countries or by FAO/OIE

National PCP focal points and national consultants







voting power







PCP stage acceptance

Until 2009

Governance Working Group: OIE, FAO, EuFMD, EC, 1 CVO

After 2010

Roadmap/Regional Advisory Group (key body in the acceptance process); currently consist of:

- o 3 CVOs
- heads of the regional epidemiology and laboratory networks
- members of the GF-TADS FMD Working Group, regional/sub-regional FAO and OIE regional offices, PCP and PVS experts and a representative from a regional organization













WE PCP-FMD regional experience

- Successful in making the West Eurasia roadmap countries united
- Successful in improving PCP-FMD stages of countries
- Built trust and commitments among the countries to a shared goal
- Promoted development and enhancing the Epi and Lab networks
- Promoted data and information sharing on:
 - Outbreaks
 - Vaccination campaigns
 - Animal movements
 - Market prices and economic data
- Promoting bilateral/multilateral agreements between the countries

















WE 8th Roadmap Recommendations

- The participants of the Roadmap to continue to work towards freedom from clinical FMD in West Eurasia by 2025
- Sub-regional FMD meetings be organized among neighboring countries to ensure (i) harmonization of vaccination strategies;
 (ii) information sharing on outbreaks, animal movements and hot spots, market prices
- To share and update information on FMD virus serotypes and topotypes both circulating and threatening the region, and on vaccines used
- To establish reasonable timeframe to submit documentation and receive feedback from the FMD Working Group and the RAG













Overall cost and benefits

Costs

- Resource expenditures for research, design and investment in measures for surveillance and control measures (e.g. vaccination), and their implementation by qualified personnel
- Opportunity costs, the benefits foregone

Benefits

- Reduce disease and losses, achieved by surveillance and control
- International trade and access to markets
- Improving/controlling other diseases
- Improved reputation













Cost and benefits of PCP Stage 2

Costs

- Vaccination
- Monitoring mechanism (relatively small)
- Revenue forgone
 - ✓ Clinical impacts in small ruminants and non-vaccinated animals
 - ✓ Limited trade and exports

Benefits

- Information valuable to risk assessment and to support potential trade/export via compartments
- Economic baseline for move to PCP stage 3 and higher













Cost and benefits of PCP Stage 3

Costs

• Likely to rise more than benefits unless:

Benefits

- Export compartments are planned based on quality monitoring system and controlled virus circulation
- Lower risk zones where costs to prevent entry of animals/infection are lower
- It is a step in the direction of Stage 4 and benefits of OIE recognized zones














Economic optimum

Optimum depends on:

- Technical production function relating production losses avoided to mitigation effort
- Monetary expenditure for a unit of mitigation resources
- 3. Monetary benefit from avoiding a unit of production losses
- 4. Resource efficiency (e.g. by public-private partnerships)



Reference: Howe et al, 2012













Public-private partnership (PPP)

- PPPs are working arrangements based on a mutual commitment, over and above that implied in any contract, between a public sector organization with any other organization outside the public sector
- PPPs create: stronger national economy, greater trust between stakeholders, improved public health, enhanced societal issues
- PPPs require: Lawful and aligns with Government policy; relevant legislations; agreement on roles and responsibilities; assessment of the costs and benefits
- PPP types in veterinary domain: transactional, collaborative, and transformative













Summary

- PCP-FMD provides a systemic framework for planning and evaluating interventions and realistic disease control objectives
- Regional agreements and collaborations such the WE roadmap provides a mechanism to create benefits for the countries involved by mitigating the risk of TADs
- PCP makes the risk associated with live animal movements (cross boarders trade) are given priority e.g. in vaccination policy
- Optimum PCP position will be different for various countries depending on their risk profile, economy etc. hence thorough socioeconomic analyses are needed at national and regional levels
- Public-private partnerships provide a platform for recourse efficiency in achieving mutual gaols











Vision for Regional Roadmaps!

